Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer
Xeloda (capecitabine) is converted to 5-fluorouracil by thymidine phosphorylase, and
cyclophosphamide is capable of upregulating the expression of thymidine phosphorylase
suggesting a synergistic effect.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
TTP (first treatment of this regimen to disease progression)
every two cycles
Yes
Zhonghua Wang, MD
Principal Investigator
Fudan University
China: Ethics Committee
200507CX
NCT00589901
August 2006
December 2008
Name | Location |
---|